-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Iovance Biotherapeutics, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2023 to Q1 2025.
- Iovance Biotherapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2025 was -$1.84M, a 30.5% decline year-over-year.
- Iovance Biotherapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2024 was -$2.83M, a 18.7% increase from 2023.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)